Akums Group, Delhi-based Contract Development and Manufacturing organization, has announced a strategic long-term agreement with a globally renowned pharmaceutical company to manufacture and supply of pharmaceutical formulations in the European market.

Under this collaboration, Akums  Group will produce and supply multiple SKUs of oral liquid formulations, which the partner company will market across various European countries.

This agreement helps boosting domestic manufacturing capabilities for global markets. The commercial supply of these products is expected to  begin in 2027 and will continue to be supplied  till 2032.

As part of this initiative, Akums Group will initiate the European approval process for its oral liquid manufacturing facility, leveraging this approval to produce the contracted products. The site and product dossier approvals are expected to be received by the end of 2026. Notably, Akums already operates two European-approved facilities for injectables and oral solids.

The total value of this agreement is estimated at €200 million (Rs 1,760 crore). As part of the agreement, Akums Group will receive an upfront payment  of €100 million (Rs 880 crore) for product development and site approval from European authorities.